Written Question · S2W-21272 · Session 2
Further to the answer to question S2W-20285 by Mr Andy Kerr on 10 November 2005, whether there have been any instances where the Scottish M…
The question
To ask the Scottish Executive, further to the answer to question S2W-20285 by Mr Andy Kerr on 10 November 2005, whether there have been any instances where the Scottish Medicines Consortium has made a recommendation on the use of a drug to NHS Scotland but has been subsequently contradicted by the National Institute for Health and Clinical Excellence’s advice to the NHS in England and Wales which has then been implemented in Scotland and, if so, whether it will provide details of such instances.
The answer
The Scottish Medicines Consortium (SMC) reviewed Pimecrolimus cream (ElidelÒ) in July 2004, and did not recommend it for use. SMC advice was:
“Pimecrolimus cream is the first topical immunomodulator licensed for the treatment of signs and symptoms of mild-to-moderate atopic dermatitis. There is no evidence that it has clinical advantage in terms of efficacy or safety when compared with the alternative treatments, which include mild-to-moderately potent topical corticosteroids. The economic case for using this preparation is unproven.”
The National Institute for Health and Clinical Excellence (NICE) issued guidance to the NHS in England and Wales on the use of tacrolimus and pimecrolimus for atopic eczema in August 2004 which allowed use of use of tacrolimus and pimecrolimus for atopic eczema in defined circumstances. This information can be found at http://www.nice.org.uk/page.aspx?o=217941.
NHS Quality Improvement Scotland (NHS QIS) validated the NICE appraisal and advised that
“NHSScotland should take account of NICE appraisals in its planning, funding and provision of services to ensure that recommended drugs or treatments are made available to meet clinical need. NHS QIS noted the differences between SMC advice and the NICE appraisal.”
Any NICE appraisal validated by NHS QIS for NHSScotland will supersede previous SMC advice for a particular medicine.
“Pimecrolimus cream is the first topical immunomodulator licensed for the treatment of signs and symptoms of mild-to-moderate atopic dermatitis. There is no evidence that it has clinical advantage in terms of efficacy or safety when compared with the alternative treatments, which include mild-to-moderately potent topical corticosteroids. The economic case for using this preparation is unproven.”
The National Institute for Health and Clinical Excellence (NICE) issued guidance to the NHS in England and Wales on the use of tacrolimus and pimecrolimus for atopic eczema in August 2004 which allowed use of use of tacrolimus and pimecrolimus for atopic eczema in defined circumstances. This information can be found at http://www.nice.org.uk/page.aspx?o=217941.
NHS Quality Improvement Scotland (NHS QIS) validated the NICE appraisal and advised that
“NHSScotland should take account of NICE appraisals in its planning, funding and provision of services to ensure that recommended drugs or treatments are made available to meet clinical need. NHS QIS noted the differences between SMC advice and the NICE appraisal.”
Any NICE appraisal validated by NHS QIS for NHSScotland will supersede previous SMC advice for a particular medicine.
In the Official Report
No contribution in the Official Report cites S2W-21272 by reference.